Abstract:Nisoldipine, a calcium antagonist of the dihydropyridine type, is the active ingredient of the controlled release nisoldipine coat-core (CC) formulation. In humans, the absorption from nisoldipine CC occurs across the entire gastrointestinal tract with an increase in bioavailability in the colon because of the lower concentrations of metabolising enzymes in the distal gut wall. Although nisoldipine is almost completely absorbed, its absolute bioavailability from the CC tablet is only 5.5%, as a result of significant first-pass metabolism in the gut and liver. Nisoldipine is a high-clearance drug with substantial interindividual and relatively lower intraindividual variability in pharmacokinetics, dependent on liver blood flow. Nisoldipine is highly (> 99%) protein bound. Its elimination is almost exclusively via the metabolic route and renal excretion of metabolites dominates over excretion in the faeces. Although nisoldipine is administered as a racemic mixture, its plasma concentrations are almost entirely caused by the eutomer as a result of highly stereoselective intrinsic clearance. Nisoldipine CC demonstrates linear pharmacokinetics in the therapeutic dose range and its steady-state pharmacokinetics are predictable from single dose data. Steady-state is reached with the second dose when the drug is given once daily and the peak-trough fluctuations in plasma concentration is minimal. Plasma-concentrations of nisoldipine increase with age. Careful dose titration according to individual clinical response is recommended in the elderly. Nisoldipine CC should not be used in patients with liver cirrhosis, though dosage adjustments in patients with renal impairment are not necessary. Inter-ethnic differences in its pharmacokinetics are not evident. Owing to inhibition of metabolising enzymes, a small dosage adjustment decrement for nisoldipine CC may be required when it is given in combination with cimetidine. Concomitant ingestion of nisoldipine with grapefruit juice should be avoided. Inducers of cytochrome P450 (CYP) 3A4, e.g. rifampicin (rifampin) and phenytoin should not be combined with nisoldipine CC, as they may reduce its bioavailability and result in a loss of efficacy. The concomitant use of other drugs which may produce marked induction or inhibition of CYP3A4 is contraindicated. Concomitant intake of the CC tablet with high fat, high calorie foods resulted in an increase in the maximum plasma concentrations of nisoldipine. The 'food-effect' can be avoided by administration of the CC tablet up to 30 minutes before the intake of food [corrected]. Plasma concentrations of nisoldipine are related to its antihypertensive effect via a maximum effect model. Nisoldipine CC once daily produce reductions in blood pressure which are maintained over 24 hours in the absence of relevant effects on heart rate.

Clinical pharmacokinetics and metabolism of nimesulide

Recent Contributions to Knowledge of the Mechanism of Action of Nimesulide

Nimesulide: some pharmaceutical and pharmacological aspects--an update

Solubility, Permeability, Anti-Inflammatory Action and In Vivo Pharmacokinetic Properties of Several Mechanochemically Obtained Pharmaceutical Solid Dispersions of Nimesulide

Novel nimesulide multicomponent solid forms: screening, synthesis, thermoanalytical study and characterization

Phase Transformation in Conformational Polymorphs of Nimesulide

Serious liver injury induced by Nimesulide: an international collaborative study

The synthesis, thermal behaviour, spectral and structural characterization, and in silico prediction of pharmacokinetic parameters of tetraalkylammonium salts of non-steroidal anti-inflammatory drug nimesulide

Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia

Pressure-temperature phase diagram of the dimorphism of the anti-inflammatory drug nimesulide

Nimesulide, a cyclooxygenase-2 preferential inhibitor, impairs renal function in the newborn rabbit

Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat

Photolysis and photocatalysis of the non-steroidal anti-inflammatory drug Nimesulide under simulated solar irradiation: Kinetic studies, transformation products and toxicity assessment

Nimesulide limits kainate-induced oxidative damage in the rat hippocampus

Comparison of the Analgesic, Antipyretic, and Anti-inflammatory Efficiency Between Nimesulide and Aspirin in Mice

Clinical pharmacokinetics of mexiletine

In Vitro Metabolism of Zolmitriptan in Rat Cytochromes Induced with Β-Naphthoflavone and the Interaction Between Six Drugs and Zolmitriptan

Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils

Clinical pharmacokinetics of nisoldipine coat-core

Optimizing Nimesulide Loaded Cubosomal Gel for Enhanced Efficacy: A Systematic Engineering Approach with Factorial Design for Topical Applications

In vivo Metabolism of Nifurtimox and the Drug-Drug Interaction Potential Including its Major Metabolites